Abstracts Archive - Page 1420 of 2425 - ACR Meeting Abstracts

Abstract Number: 18 • 2016 ACR/ARHP Annual Meeting
The Impact of Disease-Related and Contextual Factors on Work Outcomes in Chronic Inflammatory Arthritis Patients Treated with Biologics: A Systematic Review
Jenny Shu¹, Panos Lambiris² and Claire Bombardier³, ¹Department of Rheumatology, University of Toronto, Toronto, ON, Canada, ²University Health Network, Toronto, ON, Canada, ³Toronto General Hospital Research Institute, Toronto, ON, Canada
Background/Purpose: Biological therapy has been shown to have a positive effect on work outcomes, such as work participation and/or work disability in patients with chronic…
Abstract Number: 19 • 2016 ACR/ARHP Annual Meeting
Tumour Necrosis Factor Inhibition Is Associated with Weight Gain in Patients with Inflammatory Arthritis
Peter Wong¹, Alison Bowling², Cheryl Tulk³, Di Freeman³ and Hanish Bagga³, ¹Mid-North Coast Arthritis Clinic and University of New South Wales Rural Clinical School, Coffs Harbour, Australia, ²School of Health and Human Sciences, Southern Cross University, Coffs Harbour, Australia, ³Mid-North Coast Arthritis Clinic, Coffs Harbour, Australia
Background/Purpose: Targeted blockade of tumour necrosis factor (TNF) has been a major therapeutic advance in the treatment of rheumatoid arthritis (RA), psoriatic arthritis (PsA) and…
Abstract Number: 20 • 2016 ACR/ARHP Annual Meeting
Diabetes and Other Comorbidities in Rheumatoid Arthritis Patients Starting a Biologic DMARD: A Multi-Database Cohort Study
Seoyoung C. Kim^1,2, Yinzhu Jin³, Gregory Brill⁴, Jennifer Lewey^4,5, Nam-Kyong Choi³, Elisabetta Patorno⁴ and Rishi J. Desai³, ¹Rheumatology, Immunology and Allergy and Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women’s Hospital, Boston, MA, ²Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women’s Hospital, Boston, MA, ³Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women’s Hospital, Boston, MA, ⁴Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women’s Hospital/Harvard Medical School, Boston, MA, ⁵Division of Cardiology, Columbia University Medical Center, New York, NY
Background/Purpose: Patients with rheumatoid arthritis (RA) are known to have an increased comorbidity burden. Presence of diabetes or other comorbidities such as cardiovascular disease (CVD)…
Abstract Number: 21 • 2016 ACR/ARHP Annual Meeting
Outcomes of Rheumatoid Arthritis Patients with Hip Fracture
Lucy Liu¹, Joan Lo² and Malini Chandra³, ¹Internal Medicine, Kaiser Permanente, Oakland, CA, ²Endocrinology, Kaiser Permanente, Oakland, CA, ³Kaiser Permanente, Oakland, CA
Background/Purpose: Rheumatoid arthritis (RA) is a well-known risk factor for osteoporosis and hip fracture. Recent studies suggest RA patients fracture at a younger age and…
Abstract Number: 22 • 2016 ACR/ARHP Annual Meeting
Incidence and Factors Associated with the Development of Non Alcoholic Fatty Liver Disease(NAFLD) Among Patients with Rheumatoid Arthritis
Ani John¹, Angela Witt Prehn², Hebatullah Tawfik², George W. Reed³ and Joel Kremer⁴, ¹School of Health Sciences, Walden University, Minneapolis, CA, ²School of Health Sciences, Walden University, Minneapolis, MN, ³Corrona, LLC, Southborough, MA, ⁴The Center for Rheumatology, Albany Medical College, Albany, NY
Background/Purpose: NAFLD is a leading cause of chronic liver disorders, unrelated to significant alcohol use. RA and NAFLD have shared risk factors such as age,…
Abstract Number: 23 • 2016 ACR/ARHP Annual Meeting
Incidence of Non Alcoholic Fatty Liver Disease By Key Risk Factors Among Patients with Rheumatoid Arthritis
Ani John¹, Angela Witt Prehn², Hebatullah Tawfik², George W. Reed³ and Joel Kremer⁴, ¹School of Health Sciences, Walden University, Minneapolis, CA, ²School of Health Sciences, Walden University, Minneapolis, MN, ³Corrona, LLC, Southborough, MA, ⁴The Center for Rheumatology, Albany Medical College, Albany, NY
Background/Purpose: The prevalence and characteristics of patients with nonalcoholic fatty liver disease (NAFLD) have not been well characterized in the RA population. The purpose of…
Abstract Number: 24 • 2016 ACR/ARHP Annual Meeting
Modifiable Rheumatoid Arthritis Factors and Impact on Cardiovascular Risk
Katherine Liao¹, Carol J. Etzel^2,3, Jeffrey D. Greenberg⁴, Hongshu Guan⁵, Joel Kremer⁶ and Daniel H. Solomon⁷, ¹Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Boston, MA, ²Departments of Epidemiology and Biostatistics, University of Texas School of Public Health, Houston, TX, ³Corrona, LLC, Southborough, MA, ⁴New York University School of Medicine, New York, NY, ⁵Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁶The Center for Rheumatology, Albany Medical College, Albany, NY, ⁷Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Cardiovascular disease (CVD) is a major source of morbidity and mortality in RA, but current management goals follow general population recommendations without tailoring based…
Abstract Number: 25 • 2016 ACR/ARHP Annual Meeting
Have Outcomes of Patients with Inflammatory Arthritis Improved in the New Millennium? a Comparison of the 10 Year Outcome in Cohorts Recruited in 1990-4 and 2000-4
James Gwinnutt¹, Deborah P.M. Symmons^1,2, Alex J Macgregor^3,4, Jacqueline Chipping^3,4, Tarnya Marshall^3,4, Mark Lunt¹ and Suzanne M.M. Verstappen¹, ¹Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, ²NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom, ³Rheumatology, Norfolk and Norwich University Hospital, Norwich, United Kingdom, ⁴School of Medicine, Health Policy and Practice, University of East Anglia, Norwich, United Kingdom
Background/Purpose: New treatments have improved the short term outlook for patients with inflammatory polyarthritis (IP) over the past 20 years. However there is limited evidence…
Abstract Number: 26 • 2016 ACR/ARHP Annual Meeting
Rheumatoid Factor Positivity Increases All-Cause and Cancer Mortality Risk in Korean Healthy Examinees: A Kangbuk Samsung Health Study
Joong Kyong Ahn¹, Jiwon Hwang², Hyemin Jeong³, Ji Young Chae⁴, Hyungjin Kim³, Hoon-Suk Cha³ and Eun-Mi Koh³, ¹Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea, ²Department of Medicine, National Police Hospital, Seoul, Korea, The Republic of, ³Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, ⁴Departement of Internal Medicine, Bundang Jesaeng General Hospital, Seongnam, Korea, The Republic of
Background/Purpose: Several studies have reported increased overall mortality in association with rheumatoid factor (RF) in RA. However, the clinical significance including health outcomes of RF…
Abstract Number: 27 • 2016 ACR/ARHP Annual Meeting
A Rheumatologist’s Assessment of Therapy Responses (Rxresp) and Rheumatoid Factor Status (neg/pos) in 1995 Predicted Mortality through 2015 in a Community-Based Cohort of Incident Rheumatoid Arthritis Cases and Matched Control Subjects
Alfonse T. Masi¹, Azeem A. Rehman², Laura Jorgenson³ and Jean C. Aldag³, ¹University of Illinois, College of Medicine at Peoria, Peoria, IL, ²Neurosurgery, University of West Virginia Medical School, Morgantown, WV, ³Medicine, University of Illinois College of Medicine at Peoria, Peoria, IL
Background/Purpose: Greater disease severity, older age, positive serum rheumatoid factor (RF), and long-standing glucocorticoid usage contribute to increased mortality of rheumatoid arthritis (RA) patients. This…
Abstract Number: 28 • 2016 ACR/ARHP Annual Meeting
Baseline Serum Inflammatory Biomarkers at Cohort Entry in 1974 Predicted Cardiovascular Disease (CVD) Mortality from 1995 through 2015 in a Prospective, Community-Based Study of Incident Rheumatoid Arthritis (RA) Patients and Matched Non-RA (CN) Subjects
Alfonse T. Masi¹, Azeem A. Rehman², Laura Jorgenson³ and Jean C. Aldag³, ¹University of Illinois, College of Medicine at Peoria, Peoria, IL, ²Neurosurgery, University of West Virginia Medical School, Morgantown, WV, ³Medicine, University of Illinois College of Medicine at Peoria, Peoria, IL
Baseline Serum Inflammatory Biomarkers at Cohort Entry in 1974 Predicted Cardiovascular Disease (CVD) Mortality from 1995 through 2015 in a Prospective, Community-Based Study of Incident Rheumatoid…
Abstract Number: 29 • 2016 ACR/ARHP Annual Meeting
Risk of Vascular Mortality in Seniors with New-Onset Rheumatoid Arthritis
Jessica Widdifield¹, Michael Paterson², Anjie Huang³, Bindee Kuriya⁴, Carter Thorne⁵, Janet E. Pope⁶, Claire Bombardier⁷ and Sasha Bernatsky⁸, ¹McGill University, Toronto, ON, Canada, ²Institute of Clinical Evaluative Sciences, Toronto, ON, Canada, ³Institute for Clinical Evaluative Sciences, Toronto, ON, Canada, ⁴Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁵University of Toronto and Southlake Regional Health Centre, Newmarket, ON, Canada, ⁶University of Western Ontario, St Joseph's Health Care, London, ON, Canada, ⁷University of Toronto, Toronto, ON, Canada, ⁸Divisions of Rheumatology and Clinical Epidemiology, McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: RA patients are known to be at increased risk of vascular morbidity and mortality, although conflicting reports exist for incident RA patients. Our aim…
Abstract Number: 30 • 2016 ACR/ARHP Annual Meeting
Impact of Interstitial Lung Disease on Mortality of Patients with Rheumatoid Arthritis
Dam Kim¹, Soo-Kyung Cho², Chan-Bum Choi³, Jung-Yoon Choe⁴, Won Tae Chung⁵, Seung-Jae Hong⁶, Young Ok Jung⁷, Tae-Hwan Kim⁸, Tae-Jong Kim⁹, Hye-Soon Lee¹⁰, Joo Hyun Lee¹¹, Jisoo Lee¹², Shin-Seok Lee¹³, Dae-Hyun Yoo¹⁴, Bo Young Yoon¹⁵, Jin Woo Song¹⁶, Sang-Cheol Bae¹⁷ and Yoon-Kyoung Sung¹, ¹Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ²Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, The Republic of, ³Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, ⁴Medicine, Catholic university of Daegu School of medicine, Daegu, Korea, The Republic of, ⁵Rheumatology, Dong-A University Hospital, Busan, South Korea, ⁶Dept. of Rheumatology, #1 Hoeg, KyungHee University Medical Center, SEOUL, South Korea, ⁷Internal Medicine, Hallym University Kangnam Sacred Heart Hospital, Seoul, South Korea, ⁸Department of Rheumatology, Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ⁹Chonnam Nat`l University Medical School&Hospital, Chonnam, South Korea, ¹⁰Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ¹¹Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ¹²Int Medicine, Ewha Woman's Univ Schl of Med, Seoul, Korea, Republic of, ¹³Rheumatology, Chonnam National University Medical School and Hospital, Gwangju, Korea, The Republic of, ¹⁴Division of Rheumatology, Department of Internal Medicine, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ¹⁵Rheumatology/Internal medicine, Inje Iniversity Ilsan Paik Hospital, Goyang, Korea, The Republic of, ¹⁶Department of pulmonary and critical care of medicine, Asan medical center, University of Ulsan, College of Medicine, Seoul, Korea, The Republic of, ¹⁷Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, Korea, The Republic of
Background/Purpose: Some studies have supported ethnicity-related differences in the prevalence of ILD and ILD in RA; however, these results have not yet been conclusive.…
Abstract Number: 31 • 2016 ACR/ARHP Annual Meeting
Patients with Either Rheumatoid Arthritis (RA) or Axial Spondyloarthritis (axSpA) Self-Reported Flares in 24% of Assessments: An Observational Study of 86 Patients Assessed Weekly over 3 Months (ie, 1,100 assessments)
Charlotte Jacquemin¹, Herve Servy², Anna Molto³, Jeremie Sellam⁴, Violaine Foltz¹, Frédérique Gandjbakhch¹, Christophe Hudry³, Stéphane Mitrovic¹, Bruno Fautrel¹ and Laure Gossec¹, ¹Rheumatology, Pitié Salpêtrière Hospital, Paris, France, ²Sanoia, La Ciotat, France, ³Rheumatology, Cochin Hospital, Paris, France, ⁴Rheumatology, Saint-Antoine Hospital, Paris, France
Background/Purpose: The evolution of RA and axSpA is characterized by alternated periods of flares and remission. This fluctuating disease activity can be self-assessed by a…
Abstract Number: 32 • 2016 ACR/ARHP Annual Meeting
Comparison of Effects of Leukocyte-RICH and Leukocyte-Poor Platelet-RICH Plasma on PAIN and Functionality in Patients with Lateral Epicondylitis
Havva Talay Calis¹, Melek Yerlikaya², Serap Sütbeyaz³, Hatice Sayan², Nurdan Özkan², Ali Koç⁴ and Çiğdem Karakükçü⁵, ¹Departmentbof Physical Medicine and Rehabilitation, Kayseri Education and Research Hospital, Kayseri, Turkey, ²Department of Physical Medicine and Rehabilitation, Kayseri Education and Research Hospital, Kayseri, Turkey, ³Department of Physical Medicine and Rehabilitation, Kayseri Edıcation and Research Hospital, Kayseri, Turkey, ⁴Department of Radiology, Kayseri Education and Tesearch Hospital, Kayseri, Turkey, ⁵Department of Biochemistry, Kayseri Education and Research Hospital, Kayseri, Turkey
Comparison of effects of leukocyte-rich and leukocyte-poor platelet-rich plasma on pain and functionality in patients with lateral epicondylitis Melek Yerlikaya¹, Havva Talay Çalýþ¹, Serap Tomruk…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].